PW Medtech announces share repurchase plan under existing mandate

PW Medtech Group Limited announced a share repurchase plan, utilizing an existing repurchase mandate approved by shareholders. The company may repurchase up to 148,673,509 shares, representing 10% of its issued shares, before the next annual general meeting in 2026, or any potential revocation of the mandate. The company intends to repurchase shares in the open market over the coming twelve-month period, subject to market conditions and regulatory requirements. The timing, price, and volume of repurchases will depend on market conditions. The actual purchase price for each repurchase shall not be higher by 5% or more over the average closing market price for the five trading days immediately preceding each repurchase. The repurchase plan will be funded from existing cash reserves and aligns with management's belief in the company's long-term growth prospects and is intended to enhance shareholder value. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.